ASX - By Stock
|
MSB |
Re:
Pick Today's Price Range Low-High... Just for Fun
|
|
otherperspective
|
518 |
162K |
53 |
02/05/24 |
02/05/24 |
ASX - By Stock
|
518
|
162K
|
53
|
|
ASX - By Stock
|
MSB |
Re:
Pick Today's Price Range Low-High... Just for Fun
|
|
otherperspective
|
518 |
162K |
63 |
02/05/24 |
02/05/24 |
ASX - By Stock
|
518
|
162K
|
63
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
otherperspective
|
601 |
233K |
112 |
19/04/24 |
19/04/24 |
ASX - By Stock
|
601
|
233K
|
112
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
otherperspective
|
17K |
6.6M |
53 |
11/04/24 |
11/04/24 |
ASX - By Stock
|
17K
|
6.6M
|
53
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Grants Orphan Drug Designation for Revascor
|
|
otherperspective
|
272 |
100K |
48 |
28/03/24 |
28/03/24 |
ASX - By Stock
|
272
|
100K
|
48
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
|
|
otherperspective
|
551 |
203K |
60 |
28/03/24 |
28/03/24 |
ASX - By Stock
|
551
|
203K
|
60
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
|
|
otherperspective
|
551 |
203K |
94 |
26/03/24 |
26/03/24 |
ASX - By Stock
|
551
|
203K
|
94
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Completes Placement and Entitlement Offer
|
|
otherperspective
|
154 |
47K |
49 |
14/03/24 |
14/03/24 |
ASX - By Stock
|
154
|
47K
|
49
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure
|
|
otherperspective
|
549 |
174K |
64 |
11/03/24 |
11/03/24 |
ASX - By Stock
|
549
|
174K
|
64
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure
|
|
otherperspective
|
549 |
174K |
73 |
11/03/24 |
11/03/24 |
ASX - By Stock
|
549
|
174K
|
73
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure
|
|
otherperspective
|
549 |
174K |
84 |
11/03/24 |
11/03/24 |
ASX - By Stock
|
549
|
174K
|
84
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Half Year Financial Results Presentation
|
|
otherperspective
|
78 |
24K |
77 |
29/02/24 |
29/02/24 |
ASX - By Stock
|
78
|
24K
|
77
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
otherperspective
|
9.6K |
2.8M |
82 |
21/02/24 |
21/02/24 |
ASX - By Stock
|
9.6K
|
2.8M
|
82
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
otherperspective
|
9.6K |
2.8M |
63 |
31/01/24 |
31/01/24 |
ASX - By Stock
|
9.6K
|
2.8M
|
63
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
otherperspective
|
9.6K |
2.8M |
59 |
31/01/24 |
31/01/24 |
ASX - By Stock
|
9.6K
|
2.8M
|
59
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Update on Institutional Placement and Entitlement Offer
|
|
otherperspective
|
512 |
124K |
49 |
01/01/24 |
01/01/24 |
ASX - By Stock
|
512
|
124K
|
49
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Update on Institutional Placement and Entitlement Offer
|
|
otherperspective
|
512 |
124K |
70 |
31/12/23 |
31/12/23 |
ASX - By Stock
|
512
|
124K
|
70
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading Halt
|
|
otherperspective
|
716 |
199K |
71 |
01/12/23 |
01/12/23 |
ASX - By Stock
|
716
|
199K
|
71
|
|
ASX - By Stock
|
MSB |
Re:
Ann: MSB Files for FDA Designations in Congenital Heart Disease
|
|
otherperspective
|
68 |
23K |
92 |
27/11/23 |
27/11/23 |
ASX - By Stock
|
68
|
23K
|
92
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
otherperspective
|
17K |
6.6M |
57 |
07/11/23 |
07/11/23 |
ASX - By Stock
|
17K
|
6.6M
|
57
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Annual Report to Shareholders
|
|
otherperspective
|
74 |
24K |
89 |
30/10/23 |
30/10/23 |
ASX - By Stock
|
74
|
24K
|
89
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Type A Meeting with FDA
|
|
otherperspective
|
574 |
193K |
23 |
21/09/23 |
21/09/23 |
ASX - By Stock
|
574
|
193K
|
23
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Type A Meeting with FDA
|
|
otherperspective
|
574 |
193K |
104 |
21/09/23 |
21/09/23 |
ASX - By Stock
|
574
|
193K
|
104
|
|
ASX - By Stock
|
MSB |
Re:
2023 The Final Countdown
|
|
otherperspective
|
3.4K |
1.1M |
42 |
07/09/23 |
07/09/23 |
ASX - By Stock
|
3.4K
|
1.1M
|
42
|
|
ASX - By Stock
|
MSB |
Re:
Ann: MSB Annual Financial Results and Operational Update
|
|
otherperspective
|
60 |
24K |
61 |
31/08/23 |
31/08/23 |
ASX - By Stock
|
60
|
24K
|
61
|
|
ASX - By Stock
|
MSB |
Re:
CEO Itescu needs to go
|
|
otherperspective
|
904 |
276K |
70 |
23/08/23 |
23/08/23 |
ASX - By Stock
|
904
|
276K
|
70
|
|
ASX - By Stock
|
MSB |
Re:
CEO Itescu needs to go
|
|
otherperspective
|
904 |
276K |
74 |
17/08/23 |
17/08/23 |
ASX - By Stock
|
904
|
276K
|
74
|
|
ASX - By Stock
|
MSB |
Re:
CEO Itescu needs to go
|
|
otherperspective
|
904 |
276K |
50 |
10/08/23 |
10/08/23 |
ASX - By Stock
|
904
|
276K
|
50
|
|
ASX - By Stock
|
MSB |
Re:
CEO Itescu needs to go
|
|
otherperspective
|
904 |
276K |
53 |
09/08/23 |
09/08/23 |
ASX - By Stock
|
904
|
276K
|
53
|
|
ASX - By Stock
|
MSB |
Re:
The FDA is a corrupt organization.
|
|
otherperspective
|
155 |
56K |
173 |
04/08/23 |
04/08/23 |
ASX - By Stock
|
155
|
56K
|
173
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Change in substantial holding
|
|
otherperspective
|
39 |
18K |
73 |
01/08/23 |
01/08/23 |
ASX - By Stock
|
39
|
18K
|
73
|
|
ASX - By Stock
|
MSB |
Re:
How will you celebrate when FDA gives the Tick
|
|
otherperspective
|
82 |
38K |
57 |
01/08/23 |
01/08/23 |
ASX - By Stock
|
82
|
38K
|
57
|
|
ASX - By Stock
|
MSB |
Re:
2023 The Final Countdown
|
|
otherperspective
|
3.4K |
1.1M |
55 |
31/07/23 |
31/07/23 |
ASX - By Stock
|
3.4K
|
1.1M
|
55
|
|
ASX - By Stock
|
MSB |
Re:
2023 The Final Countdown
|
|
otherperspective
|
3.4K |
1.1M |
98 |
31/07/23 |
31/07/23 |
ASX - By Stock
|
3.4K
|
1.1M
|
98
|
|
ASX - By Stock
|
MSB |
Re:
2023 The Final Countdown
|
|
otherperspective
|
3.4K |
1.1M |
106 |
27/07/23 |
27/07/23 |
ASX - By Stock
|
3.4K
|
1.1M
|
106
|
|
ASX - By Stock
|
MSB |
Re:
2023 The Final Countdown
|
|
otherperspective
|
3.4K |
1.1M |
86 |
24/07/23 |
24/07/23 |
ASX - By Stock
|
3.4K
|
1.1M
|
86
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
otherperspective
|
17K |
6.6M |
57 |
20/07/23 |
20/07/23 |
ASX - By Stock
|
17K
|
6.6M
|
57
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
otherperspective
|
17K |
6.6M |
128 |
19/07/23 |
19/07/23 |
ASX - By Stock
|
17K
|
6.6M
|
128
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Third Quarter Results Presentation
|
|
otherperspective
|
55 |
21K |
62 |
30/05/23 |
30/05/23 |
ASX - By Stock
|
55
|
21K
|
62
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
otherperspective
|
17K |
6.6M |
97 |
25/05/23 |
25/05/23 |
ASX - By Stock
|
17K
|
6.6M
|
97
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Completes Private Placement
|
|
otherperspective
|
71 |
37K |
115 |
26/04/23 |
26/04/23 |
ASX - By Stock
|
71
|
37K
|
115
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Schedules GvHD Pre-License Manufacturing Inspection
|
|
otherperspective
|
275 |
110K |
57 |
22/03/23 |
22/03/23 |
ASX - By Stock
|
275
|
110K
|
57
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Schedules GvHD Pre-License Manufacturing Inspection
|
|
otherperspective
|
275 |
110K |
114 |
22/03/23 |
22/03/23 |
ASX - By Stock
|
275
|
110K
|
114
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L
|
|
otherperspective
|
1.0K |
386K |
65 |
08/03/23 |
08/03/23 |
ASX - By Stock
|
1.0K
|
386K
|
65
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L
|
|
otherperspective
|
1.0K |
386K |
83 |
08/03/23 |
08/03/23 |
ASX - By Stock
|
1.0K
|
386K
|
83
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L
|
|
otherperspective
|
1.0K |
386K |
124 |
08/03/23 |
08/03/23 |
ASX - By Stock
|
1.0K
|
386K
|
124
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Second Quarter Results Presentation
|
|
otherperspective
|
117 |
30K |
51 |
28/02/23 |
28/02/23 |
ASX - By Stock
|
117
|
30K
|
51
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Second Quarter Results Presentation
|
|
otherperspective
|
117 |
30K |
51 |
28/02/23 |
28/02/23 |
ASX - By Stock
|
117
|
30K
|
51
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Second Quarter Results Presentation
|
|
otherperspective
|
117 |
30K |
57 |
28/02/23 |
28/02/23 |
ASX - By Stock
|
117
|
30K
|
57
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Completes Resubmission of BLA to FDA for SR-aGVHD
|
|
otherperspective
|
914 |
287K |
75 |
20/02/23 |
20/02/23 |
ASX - By Stock
|
914
|
287K
|
75
|
|